Search results
Results from the WOW.Com Content Network
In the United States, SIRVA was added to the list of compensable injuries on the Vaccine Injury Table used by the National Vaccine Injury Compensation Program in 2017. [6] [7] This inclusion allowed persons claiming an injury to seek compensation from a government fund set up under the program, while immunizing vaccine manufacturers and administrators from legal liability.
Scurvy is a deficiency disease (state of malnutrition) resulting from a lack of vitamin C (ascorbic acid). [1] Early symptoms of deficiency include weakness, fatigue, and sore arms and legs. [ 1 ] [ 2 ] Without treatment, decreased red blood cells , gum disease, changes to hair, and bleeding from the skin may occur.
Kids receive one-third of the standard dose given to adults, so they can generally expect fewer side effects. One chart shows the most common side effects for kids after each dose of Pfizer's ...
That’s a common reaction: A recent study found that 30-90% of people who got the COVID vaccine experienced some type of side effect, which can appear within 1–3 days after you get immunized.
In April 2023, Pfizer published their interim results of their phase III study of a RSV vaccine for adults age 60 and older in over 34,000 participants. One dose of the vaccine was 67% efficacious in preventing infections with at least two symptoms and it was 86% effective against more severe disease, in people with three related symptoms.
Older people who receive their second shot of Pfizer’s coronavirus vaccine 12 weeks after the first jab produce three-and-a-half times more antibodies than those who wait three weeks, according ...
It also stated that people with "severely weakened" immune systems can receive an extra dose of either the Pfizer-BioNTech vaccine or the Moderna vaccine starting at least 28 days after their second dose. [84] The final approval to provide booster shots in the European Union will be decided by each national government. [291]
With booster doses of Pfizer's COVID-19 vaccine now authorized in the U.S., government advisers reconvened on Thursday to tackle the most contentious question yet: Exactly who should roll up their ...